| Company Name: |
Aikon International Limited
|
| Tel: |
17714375163 |
| Email: |
hywu@aikonchem.com |
| Products Intro: |
Product Name:3-(Ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine
CAS:2392951-29-8
Purity:95%+ Package:1g;5g;10g
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:Relutrigine/PRAX-562
CAS:2392951-29-8
Purity:98%+ HPLC Package:10mg，500mg，1g，2g，5g，10g，more
|
1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- manufacturers
- Relutrigine
-
- $2180.00
-
2026-04-21
- CAS:2392951-29-8
- Purity: 99.68%
- Supply Ability: 10g
|
| | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Basic information |
| Product Name: | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- | | Synonyms: | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-;Relutrigine/PRAX-562;3-(Ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine;Relutrigine | | CAS: | 2392951-29-8 | | MF: | C15H11F6N5O2 | | MW: | 407.27 | | EINECS: | | | Product Categories: | | | Mol File: | 2392951-29-8.mol | ![1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Structure](CAS/20210305/GIF/2392951-29-8.gif) |
| | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Chemical Properties |
| density | 1.57±0.1 g/cm3(Predicted) | | pka | -2.13±0.34(Predicted) | | form | Solid | | color | White to light yellow |
| | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Usage And Synthesis |
| Description | Relutrigine is a sodium channel blocker. | | Uses | Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent INa induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC50 values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity[1]. | | in vivo | Relutrigine (0.3-40 mg/kg; po; single dose) exhibits protection in maximal electroshock seizure (MES) induced tonic hindlimb seizures, and reduces movement distance with dose-dependent manner in male CD-1 mice model[1]. | Animal Model: | Male CD-1 mice (~35 g; MES)[1]. | | Dosage: | 0.3, 1, 3, 10, 20 and 40 mg/kg. | | Administration: | Oral gavage; single dose. | | Result: | Showed full anticonvulsant efficacy without affecting locomotor activity. |
| | References | [1] Kahlig KM, et al. The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia. 2022 Mar;63(3):697-708. DOI:10.1111/epi.17149 |
| | 1,2,4-Triazolo[4,3-a]pyrazine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Preparation Products And Raw materials |
|